| Daniele Rottkamp, MD | |
|
795 El Camino Real, Palo Alto, CA 94301-2302 | |
| (650) 853-2981 | |
| Not Available |
| Full Name | Daniele Rottkamp |
|---|---|
| Gender | Female |
| Speciality | Endocrinology |
| Experience | 18 Years |
| Location | 795 El Camino Real, Palo Alto, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1740492925 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sutter Bay Medical Foundation | 4284538778 | 2941 |
| University Of California San Francisco | 4486567229 | 1298 |
News Archive
Today, at the Engineering in Medicine and Biology Conference in Buenos Aires (Argentina), imec and its project partners announce the launch of the European Seventh Framework Project MIRACLE. The MIRACLE project aims at developing an operational lab-on-chip for the isolation and detection of circulating and disseminated tumor cells in blood.
St. Jude Medical, Inc., a global medical device company, today announced the publication of results from an economic evaluation of the landmark FAME (Fractional Flow Reserve (FFR) vs. Angiography in Multivessel Evaluation) trial, which confirmed FFR-guided percutaneous coronary intervention (PCI) in patients with multivessel coronary artery disease improves patient outcomes and offers cost-saving benefits to the U.S. healthcare system.
For the first time, national data on 30-day mortality for patients with breast and lung cancer treated with chemotherapy have been collected and analysed in order to help clinical teams review and improve patient care, and identify groups of patients who may have additional needs.
BioCryst Pharmaceuticals, Inc. announced financial results for the quarter and nine months ended September 30, 2009 and provided a corporate update regarding clinical programs and potential emergency use of intravenous (i.v.) peramivir.
› Verified 8 days ago
| Entity Name | Regents Of The University Of California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881763597 PECOS PAC ID: 4284547274 Enrollment ID: O20031106000389 |
News Archive
Today, at the Engineering in Medicine and Biology Conference in Buenos Aires (Argentina), imec and its project partners announce the launch of the European Seventh Framework Project MIRACLE. The MIRACLE project aims at developing an operational lab-on-chip for the isolation and detection of circulating and disseminated tumor cells in blood.
St. Jude Medical, Inc., a global medical device company, today announced the publication of results from an economic evaluation of the landmark FAME (Fractional Flow Reserve (FFR) vs. Angiography in Multivessel Evaluation) trial, which confirmed FFR-guided percutaneous coronary intervention (PCI) in patients with multivessel coronary artery disease improves patient outcomes and offers cost-saving benefits to the U.S. healthcare system.
For the first time, national data on 30-day mortality for patients with breast and lung cancer treated with chemotherapy have been collected and analysed in order to help clinical teams review and improve patient care, and identify groups of patients who may have additional needs.
BioCryst Pharmaceuticals, Inc. announced financial results for the quarter and nine months ended September 30, 2009 and provided a corporate update regarding clinical programs and potential emergency use of intravenous (i.v.) peramivir.
› Verified 8 days ago
| Entity Name | Sutter Bay Medical Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013950807 PECOS PAC ID: 4284538778 Enrollment ID: O20031125000909 |
News Archive
Today, at the Engineering in Medicine and Biology Conference in Buenos Aires (Argentina), imec and its project partners announce the launch of the European Seventh Framework Project MIRACLE. The MIRACLE project aims at developing an operational lab-on-chip for the isolation and detection of circulating and disseminated tumor cells in blood.
St. Jude Medical, Inc., a global medical device company, today announced the publication of results from an economic evaluation of the landmark FAME (Fractional Flow Reserve (FFR) vs. Angiography in Multivessel Evaluation) trial, which confirmed FFR-guided percutaneous coronary intervention (PCI) in patients with multivessel coronary artery disease improves patient outcomes and offers cost-saving benefits to the U.S. healthcare system.
For the first time, national data on 30-day mortality for patients with breast and lung cancer treated with chemotherapy have been collected and analysed in order to help clinical teams review and improve patient care, and identify groups of patients who may have additional needs.
BioCryst Pharmaceuticals, Inc. announced financial results for the quarter and nine months ended September 30, 2009 and provided a corporate update regarding clinical programs and potential emergency use of intravenous (i.v.) peramivir.
› Verified 8 days ago
| Entity Name | University Of California San Francisco |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861578973 PECOS PAC ID: 4486567229 Enrollment ID: O20031212000897 |
News Archive
Today, at the Engineering in Medicine and Biology Conference in Buenos Aires (Argentina), imec and its project partners announce the launch of the European Seventh Framework Project MIRACLE. The MIRACLE project aims at developing an operational lab-on-chip for the isolation and detection of circulating and disseminated tumor cells in blood.
St. Jude Medical, Inc., a global medical device company, today announced the publication of results from an economic evaluation of the landmark FAME (Fractional Flow Reserve (FFR) vs. Angiography in Multivessel Evaluation) trial, which confirmed FFR-guided percutaneous coronary intervention (PCI) in patients with multivessel coronary artery disease improves patient outcomes and offers cost-saving benefits to the U.S. healthcare system.
For the first time, national data on 30-day mortality for patients with breast and lung cancer treated with chemotherapy have been collected and analysed in order to help clinical teams review and improve patient care, and identify groups of patients who may have additional needs.
BioCryst Pharmaceuticals, Inc. announced financial results for the quarter and nine months ended September 30, 2009 and provided a corporate update regarding clinical programs and potential emergency use of intravenous (i.v.) peramivir.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Daniele Rottkamp, MD 325 Distel Cir, Los Altos, CA 94022-1408 Ph: (650) 853-2981 | Daniele Rottkamp, MD 795 El Camino Real, Palo Alto, CA 94301-2302 Ph: (650) 853-2981 |
News Archive
Today, at the Engineering in Medicine and Biology Conference in Buenos Aires (Argentina), imec and its project partners announce the launch of the European Seventh Framework Project MIRACLE. The MIRACLE project aims at developing an operational lab-on-chip for the isolation and detection of circulating and disseminated tumor cells in blood.
St. Jude Medical, Inc., a global medical device company, today announced the publication of results from an economic evaluation of the landmark FAME (Fractional Flow Reserve (FFR) vs. Angiography in Multivessel Evaluation) trial, which confirmed FFR-guided percutaneous coronary intervention (PCI) in patients with multivessel coronary artery disease improves patient outcomes and offers cost-saving benefits to the U.S. healthcare system.
For the first time, national data on 30-day mortality for patients with breast and lung cancer treated with chemotherapy have been collected and analysed in order to help clinical teams review and improve patient care, and identify groups of patients who may have additional needs.
BioCryst Pharmaceuticals, Inc. announced financial results for the quarter and nine months ended September 30, 2009 and provided a corporate update regarding clinical programs and potential emergency use of intravenous (i.v.) peramivir.
› Verified 8 days ago
Daniel Joseph Razzano, M.D. Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 3801 Miranda Ave, Palo Alto, CA 94304 Phone: 650-493-5000 | |
Mahnoosh Kuhbanani Seifoddini, M.D. Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 3801 Miranda Ave, Va Palo Alto Health Care System (111stc), Palo Alto, CA 94304 Phone: 209-946-3400 | |
Dr. Yusra Nazar Hussain, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 770 Welch Rd, Suite # 250, Palo Alto, CA 94304 Phone: 650-328-1676 Fax: 650-445-0911 | |
Dr. David Yao, M.D. Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 3801 Miranda Ave, Medical Services (111a), Palo Alto, CA 94304 Phone: 650-493-5000 | |
Dr. Franklin Perry, M.D. Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 2175 Park Blvd, Palo Alto, CA 94306 Phone: 650-330-3688 Fax: 650-330-3686 | |
Dr. Ryan Arthur Mcconnell, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 795 El Camino Real, Palo Alto, CA 94301 Phone: 650-853-2972 | |
Dr. Ann Margaretha Lowe, M.D. Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 420 Cambridge Ave, Unit 3, Palo Alto, CA 94306 Phone: 650-323-6614 |